Astrazeneca invests $2bn in cancer drug tie-up Markets Astrazeneca has invested $2bn in US pharmaceutical firm Summit Therapeutics as part of a blockbuster cancer research tie-up. The FTSE 100 drugs giant has agreed to buy 109,000 shares in Nasdaq-listed Summit for $18.36 per share as part of the deal. Shares in Astrazeneca jumped by 1.4 per cent to 12,664p in early trading. The tie-up [...]
Astrazeneca chief blasts Europe for ‘putting citizens’ health at risk’ healthcare Europe is putting its “ability to protect the health of its own people at risk” by not investing enough, the chief executive of FTSE 100 giant Astrazeneca has warned. Pascal Soriot added that the continent is “falling behind” in attracting R&D and manufacturing investment and needs to “invest more in what really matters to it”. [...]
Meet the founder searching for the ‘holy grail’ of cancer treatment Founder profile Jennifer Sieg speaks with Hilmar Warenius about how his discovery of a new type of cancer treatment could be well on its way to revolutionising the pharmaceutical industry
Angle agrees deal with Astrazeneca for tech to kill cancer cells April 24, 2024 This is expected to be driven by an increase in the use of combination therapy for the treatment of drug-resistant cancers and the need for novel targeted medicines for cancer treatment.